{
  "first_published_at": "2012-08-20", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON180637", 
  "title": "Simvastatin: updated advice on drug interactions - updated contraindications", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\", \"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\", \"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 103, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology", 
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Simvastatin: updated advice on drug interactions - updated contraindications</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: August 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Considering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in changes to the simvastatin prescribing information, including contraindications to concomitant use with certain medicines.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>We have previously communicated on the increased risk of myopathy associated with use of high-dose simvastatin (80 mg daily) &#8211; see <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085169\">Drug Safety Update May 2010</a>.</p>\n\n<p>Considering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in further changes to the simvastatin prescribing information.&#160;</p>\n\n<p>The changes include contraindications to concomitant use with certain medicines and maximum dose recommendations when simvastatin is taken with a number of other medicines, as these interactions may increase plasma concentrations of simvastatin which is associated with an increased risk of myopathy and/or rhabdomyolysis. Key points to note are that:</p>\n\n<ul>\n<li>Simvastatin is now contraindicated with ciclosporin, danazol and gemfibrozil</li>\n\n<li>The maximum recommended dose for simvastatin in conjunction with amlodipine or diltiazem is now 20 mg/day<br />\n</li>\n</ul>\n\n<p>A full updated listing of all the interactions is provided in the table below.</p>\n\n<table border=\"1\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\">\n<tr style=\" background-color: #BFBFBF;\">\n<td colspan=\"2\" style=\" text-align: center; width: 100%;\">\n<h3><strong>Drug interactions associated with increased risk of myopathy/rhabdomyolysis</strong></h3>\n</td>\n</tr>\n\n<tr style=\" background-color: #D8D8D8;\">\n<td width=\"50%\"><strong>Interacting agents</strong></td>\n<td width=\"50%\"><strong>Prescribing recommendations</strong></td>\n</tr>\n\n<tr>\n<td width=\"50%\">Itraconazole<br />\nKetoconazole<br />\nPosaconazole<br />\nErythromycin<br />\nClarithromycin<br />\nTelithromycin<br />\nHIV protease inhibitors (eg, nelfinavir)<br />\nNefazodone<br />\nCiclosporin<br />\nDanazol<br />\nGemfibrozil</td>\n<td width=\"50%\">Contraindicated with simvastatin</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Other fibrates (except fenofibrate)</td>\n<td width=\"50%\">Do not exceed 10 mg simvastatin daily</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Amiodarone<br />\nAmlodipine<br />\nVerapamil<br />\nDiltiazem</td>\n<td width=\"50%\">Do not exceed 20 mg simvastatin daily</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Fusidic acid</td>\n<td width=\"50%\">Patients should be closely monitored. Temporary suspension of simvastatin treatment may be considered.</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Grapefruit juice</td>\n<td width=\"50%\">Avoid grapefruit juice when taking simvastatin</td>\n</tr>\n</table>\n\n<p>&#160;</p>\n\n<p><strong>Further information:</strong><br />\nBNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/128041.htm?q=simvastain&#38;t=search&#38;ss=text&#38;p=1#_128041\">2.12: Lipid-regulating drugs</a>&#160;<br />\n&#160;</p>\n\n<p><em>Article citation: Drug Safety Update August 2012, vol 6, issue 1: S1</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>We have previously communicated on the increased risk of myopathy associated with use of high-dose simvastatin (80 mg daily) &#8211; see <a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085169\">Drug Safety Update May 2010</a>.</p>\n\n<p>Considering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in further changes to the simvastatin prescribing information.&#160;</p>\n\n<p>The changes include contraindications to concomitant use with certain medicines and maximum dose recommendations when simvastatin is taken with a number of other medicines, as these interactions may increase plasma concentrations of simvastatin which is associated with an increased risk of myopathy and/or rhabdomyolysis. Key points to note are that:</p>\n\n<ul>\n<li>Simvastatin is now contraindicated with ciclosporin, danazol and gemfibrozil</li>\n\n<li>The maximum recommended dose for simvastatin in conjunction with amlodipine or diltiazem is now 20 mg/day<br>\n</li>\n</ul>\n\n<p>A full updated listing of all the interactions is provided in the table below.</p>\n\n<table border=\"1\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\">\n<tr style=\" background-color: #BFBFBF;\">\n<td colspan=\"2\" style=\" text-align: center; width: 100%;\">\n<h3><strong>Drug interactions associated with increased risk of myopathy/rhabdomyolysis</strong></h3>\n</td>\n</tr>\n\n<tr style=\" background-color: #D8D8D8;\">\n<td width=\"50%\"><strong>Interacting agents</strong></td>\n<td width=\"50%\"><strong>Prescribing recommendations</strong></td>\n</tr>\n\n<tr>\n<td width=\"50%\">Itraconazole<br>\nKetoconazole<br>\nPosaconazole<br>\nErythromycin<br>\nClarithromycin<br>\nTelithromycin<br>\nHIV protease inhibitors (eg, nelfinavir)<br>\nNefazodone<br>\nCiclosporin<br>\nDanazol<br>\nGemfibrozil</td>\n<td width=\"50%\">Contraindicated with simvastatin</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Other fibrates (except fenofibrate)</td>\n<td width=\"50%\">Do not exceed 10 mg simvastatin daily</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Amiodarone<br>\nAmlodipine<br>\nVerapamil<br>\nDiltiazem</td>\n<td width=\"50%\">Do not exceed 20 mg simvastatin daily</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Fusidic acid</td>\n<td width=\"50%\">Patients should be closely monitored. Temporary suspension of simvastatin treatment may be considered.</td>\n</tr>\n\n<tr>\n<td width=\"50%\">Grapefruit juice</td>\n<td width=\"50%\">Avoid grapefruit juice when taking simvastatin</td>\n</tr>\n</table>\n\n<p>&#160;</p>\n\n<p><strong>Further information:</strong><br>\nBNF section <a target=\"_blank\" href=\"http://www.medicinescomplete.com/mc/bnf/current/128041.htm?q=simvastain&amp;t=search&amp;ss=text&amp;p=1#_128041\">2.12: Lipid-regulating drugs</a>&#160;<br>\n&#160;</p>\n\n<p><em>Article citation: Drug Safety Update August 2012, vol 6, issue 1: S1</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-08-01", 
  "date_last_modified": "2013-01-29", 
  "_assets": [], 
  "_item_id": 103, 
  "summary": "", 
  "body": "Article date: August 2012\n\nWe have previously communicated on the increased risk of myopathy associated with use of high-dose simvastatin (80 mg daily) – see [Drug Safety Update May 2010](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085169).\n\nConsidering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in further changes to the simvastatin prescribing information. \n\nThe changes include contraindications to concomitant use with certain medicines and maximum dose recommendations when simvastatin is taken with a number of other medicines, as these interactions may increase plasma concentrations of simvastatin which is associated with an increased risk of myopathy and/or rhabdomyolysis. Key points to note are that:  \n  \n  * Simvastatin is now contraindicated with ciclosporin, danazol and gemfibrozil  \n  * The maximum recommended dose for simvastatin in conjunction with amlodipine or diltiazem is now 20 mg/day  \n  \n  \nA full updated listing of all the interactions is provided in the table below.  \n  \n### Drug interactions associated with increased risk of myopathy/rhabdomyolysis\n\n |   \nInteracting agents |   | Prescribing recommendations |   \nItraconazole Ketoconazole Posaconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors (eg, nelfinavir) Nefazodone Ciclosporin Danazol Gemfibrozil |   | Contraindicated with simvastatin |   \nOther fibrates (except fenofibrate) |   | Do not exceed 10 mg simvastatin daily |   \nAmiodarone Amlodipine Verapamil Diltiazem |   | Do not exceed 20 mg simvastatin daily |   \nFusidic acid |   | Patients should be closely monitored. Temporary suspension of simvastatin treatment may be considered. |   \nGrapefruit juice |   | Avoid grapefruit juice when taking simvastatin | \n\n \n\nFurther information:  \nBNF section [2.12: Lipid-regulating drugs](http://www.medicinescomplete.com/mc/bnf/current/128041.htm?q=simvastain&t=search&ss=text&p=1#_128041)   \n \n\nArticle citation: Drug Safety Update August 2012, vol 6, issue 1: S1\n"
}